Search

A brand new EHA website!

You may already have noticed the new EHA look & feel.  We are proud to share it with you already.  We are currently migrating all our pages and related information.

Read more

Meeting program

Saturday, November 4*All times are in EET.

Read more

Faculty Information

We are honored that you have agreed to be a part of the faculty for the EHA-GBMTA-AHA Hematology Tutorial on New Aspects in Diagnostic Choices and Treatment Options of Hematological Malignancies, scheduled to be held on October 18-20, 2024 in Tbilisi, Georgia.…

Read more

EHA-SWG Diagnosis Teaser Meeting

On February 17 the 'teaser' meeting "Join the conversation on integrated diagnosis" with Prof MC Béne and key opinion experts took place virtually. Missed the live teaser? No worries, you can still watch the recording until March 17, 2022.

Read more

Publications

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.

Read more

Great new opportunity for the YoungEHA community!

Great new opportunity for the YoungEHA community!
by Dr Nuno Borges, YoungEHA committee

The European Medicines Agency (EMA) has launched the 'Collaborating Expert Programme' - an initiative which aims to increase co-operation between European countries to improve research into medicinal products.…

Read more

Recommendation for hematologists in COVID-19 crisis

Recommendations for hematologists in COVID-19 crisis
COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in patients with active cancer. It should be taken seriously and managed rigorously without jeopardizing the curative chance of individual cancer patients.

Read more

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Read more